Eli Lilly has launched a new ad for its prescription weight-loss medicine Zepbound, titled “A Different Way: $299,” linking the creative to a recent move to lower out-of-pocket costs for some patients. The spot began airing in early December, shortly after the company announced reduced self-pay pricing for single-dose vials of Zepbound through its LillyDirect platform.
Zepbound contains tirzepatide, a once-weekly injectable medicine approved in the US for chronic weight management in adults with obesity, or in some adults with overweight who have at least one weight-related medical condition, when used alongside diet and physical activity. It is also approved for adults with moderate-to-severe obstructive sleep apnea and obesity. The recommended maintenance doses for weight reduction and long-term management are 5 mg, 10 mg or 15 mg administered subcutaneously once per week.
In the commercial, Zepbound is introduced as a weekly treatment option that can support both weight loss and weight maintenance. The ad noted that with the 15 mg dose, some people in clinical studies lost up to about 48 lbs on average, corresponding to roughly 21% body-weight reduction, with a reminder that individual results may vary.
Affordability is woven into the message through a short reference to available savings options. The campaign’s title points to Lilly’s recent pricing update, under which the 2.5 mg starting dose of Zepbound in a single-dose vial is available for $299 per month for eligible patients through the company’s Zepbound Self Pay Journey Program on LillyDirect.
Lilly has said the move is intended to lower financial barriers and provide additional access pathways for adults seeking obesity treatment.
Against the current surge of interest in weight-loss therapies, there is heightened attention on obesity as a chronic disease and on the role of incretin-based medicines in long-term care.
In December, the World Health Organization (WHO) released its first global guideline on the use of GLP-1-based medicines for obesity, recognizing their potential role within comprehensive, ongoing treatment while also highlighting the importance of access and affordability.
More recently, Health Canada issued warnings about unauthorized and counterfeit versions of GLP-1 medicines entering the market, noting that some products being sold online and in retail settings had not been reviewed for safety, effectiveness or quality and could pose risks.
Lilly has also reported recent clinical progress across its broader obesity portfolio. In mid-December, the company announced Phase III results from the ATTAIN-MAINTAIN study showing that participants who switched from injectable therapies such as Zepbound to the investigational oral GLP-1 receptor agonist orforglipron were able to maintain most of their prior weight loss over one year. Lilly has since submitted orforglipron to the FDA for the treatment of obesity.
Other clinical research in obesity therapeutics continues to advance alongside Zepbound’s rollout. Eli Lilly’s next-gen triple-agonist candidate retatrutide has shown notable weight reduction in a Phase III study reported in December 2025.
Meanwhile, Structure Therapeutics reported positive mid-stage results for its oral GLP-1 agonist aleniglipron in adults with obesity, with plans to initiate a Phase III program by mid-2026 following discussions with the FDA.
And, in January, Viking Therapeutics reported the peer-reviewed publication of Phase II data for its dual GLP-1/GIP receptor agonist VK2735 and confirmed that the program has progressed into the VANQUISH Phase III registrational studies, with one pivotal trial fully enrolled and a second expected to complete enrollment in early 2026.
Within this broader landscape, “A Different Way: $299,” centers on two elements that are explicit in the creative itself: the clinical profile of a once-weekly therapy approved for chronic weight management, paired with messaging around greater convenience and improved affordability.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN